Learning Objectives

• To recognize the importance of clinical, laboratory, and morphologic manifestations of glomerular diseases of the kidneys to enhance skills in diagnostic and prognostic evaluation of these disorders.
• To discuss and interpret the potential pathogenetic mechanisms that underlie primary and secondary forms of glomerular diseases.
• To describe the rationale, efficacy, and safety of current and emerging therapeutic approaches to primary and secondary glom- erular diseases of the kidneys.

It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN's educational activities are expected to disclose all their and their life spouse/partner's financial relationships with “ineligible companies” within the prior 24 months as well as other non-financial interests. (“Ineligible companies” are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.) Participants should note that the use of products outside U.S. Food and Drug Administration (FDA) approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications.

The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in educational activities, but rather to ensure that these activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for this activity to complete disclosure forms on the ASN website. Responses are listed below.

Disclosures have been reviewed and assessed by ASN. All relationships with ineligible companies have been identified and all relevant financial relationships have been mitigated.

View the full ASN Conflict of Interest and Disclosure Policy: https://www.asn-online.org/education/cme/coi-disclosure.pdf.

EDITORS:

Alice M. Sheridan, MD—Employer(s): Brigham and Women’s Hospital; No additional relevant financial relationship(s) with ineligible companies to disclose.

Martina M. McGrath, MBChB, FASN—Employer(s): Brigham and Women’s Hospital; VA Boston Medical Center; No additional relevant financial relationship(s) with ineligible companies to disclose.

EDITORIAL AUTHORS:

Ali G. Gharavi, MD—Employer(s): Columbia University; Consultancy: Astra Zeneca Center for genomics research, Goldfinch Bio: Actio biosciences, Novartis: Travere; Ownership Interest: Actio biosciences; Research Funding: Renal Research Institute, Natera; Honoraria: Sanofi, Alnylam; Advisory or Leadership Role: Editorial board: JASN and Journal of Nephrology

Emily Groopman, MD, PhD—Employer(s): Columbia University; No additional relevant financial relationship(s) with ineligible companies to disclose.

AUTHORS:

Wooin Ahn, MD, PhD—Employer(s): Skidmore, Owings & Merrill; Patents or Royalties: Wolters Kluwer

Fernando C. Fervenza, MD, PhD, FASN—Employer(s): Mayo Clinic; Consultancy: Alexion Pharmaceuticals, ByoCrystal, Takeda, Novartis, Galapagos, GSK, Otsuka; Research Funding: Genentech, Hoffman La Roche, Janssen Pharmaceutical, Chemocentryx, Retrophin, Morphosys; Honoraria: UpToDate; Advisory or Leadership Role: UpToDate, Kidney International, Nephrology, Nephrology Dialysis and Transplantation, Journal of the American Society of Nephrology

Stephen P. McAdoo, MA, MBBS, PhD—Employer(s): Imperial College London; Consultancy: GSK, Vifor; Research Funding: Therini Bio; Honoraria: Rigel Pharmaceuticals, ThermoFisher Scientific, Celltrion; Advisory or Leadership Role: Co-chair United Kingdom & Ireland Vasculitis Society (unpaid)

Amy K. Mottl, MD, MPH, FASN—Employer(s): University of North Carolina at Chapel Hill; Consultancy: Bayer, Chinook; Research Funding: Alexion, Aurinia, Bayer, Calliditas, Duke Clinical Research Institute, Pfizer, University of Pennsylvania; Honoraria: Bayer, UpToDate; Advisory or Leadership Role: Bayer, Chinook

Susanne B. Nicholas, MD, PhD, MPH—Employer(s): David Geffen School of Medicine at UCLA; Consultancy: Janssen Pharmaceutical, Inc., Bayer, Goldfinch, Inc., Travere Pharmaceutical, GeorgeClinical, Boehringer Ingelheim Pharmaceutical, AstraZeneca, Terasaki Biomedical Innovation., NovoNordisk; Research Funding: Bayer, Goldfinch, Inc., Travere, Terasaki Institute of Biomedical Innovation; Honoraria: Janssen Pharmaceutical, Inc., Bayer, George Clinical, Boehringer Ingelheim/Lilly Pharmaceutical, AstraZeneca, NovoNordisk; Patents or Royalties: UCLA; Advisory or Leadership Role: Volunteer: President of the National Kidney Foundation of Southern California and Southern Nevada Medical Advisory, Board Executive Committee: Board of Directors, President-Elect Women of Nephrology, Paid: Janssen Pharmaceutical, Boehringer Ingelheim/Lilly Pharmaceutical, Bayer, NovoNordisk, AstraZeneca, Janssen; Speakers Bureau: Janssen Pharmaceutical; Bayer; Boehringer Ingelheim Pharmaceutical; Astra Zeneca

Charles D. Pusey, MD, FASN—Employer(s): Imperial College London; Consultancy: Vifor, Alentis; Honoraria: Med Update Europe, Amgen; Advisory or Leadership Role: Clinical Journal of the American Society of Nephrology

Meghan E. Sise, MD, MS—Employer(s): Massachusetts General Hospital; Consultancy: Travere, Mallinckrodt, Novartis; Research Funding: Gilead Sciences, Abbvie, Merck, EMD-Serono, Angion

Ladan Zand, MD—Employer(s): Mayo Clinic, Rochester, MN; Research Funding: Mallinckrodt, Janssen pharmaceuticals, Genentech

ASN STAFF:

Suzanne P. Armstrong, MA—Employer(s): American Society of Nephrology; No additional relevant financial relationship(s) with ineligible companies to disclose.

Commercial Support

There is no commercial support for this issue.

The nephSAP editorial team and the KSAP editorial board extend their sincere appreciation to the following reviewers. Their efforts and insights help improve the quality of these postgraduate education offerings. 

nephSAP Review Panel, Volume 21, Number 5, December 2022

• Manohar Bairy, MBBS, MD, Tan Tock Seng Hospital, SINGAPORE
• Anip Bansal, MD, FASN, University of Colorado Anschutz Medical Campus, United States
• Khaled Boubes, MD, FASN, The Ohio State University, United States
• Kiran M. Goli, MD, FASN, Kidney Care Specialists, LLC, United States
• Elvira O. Gosmanova, MD, FASN, Albany Medical College, United States
• Insara Jaffer Sathick, MBBS, Memorial Sloan Kettering Cancer Center, United States
• George Jarad, MD, Washington University School of Medicine, United States
• Poonum Khalid, II,, MBBS, Nishtar medical university Multan, Pakistan
• Sana F. Khan, MD, University of Virginia, United States
• Norbert H. Lameire, MD, PhD, Ghent University, Belgium
• Amr El-Husseini Mohamed, MD, PhD, University of Kentucky, United States
• Chanigan Nilubol, MD, MedStar Georgetown University Hospital, United States
• Arvind Ponnusamy, Royal Preston Hospital, United Kingdom
• Anand M. Ravindran, MD, MBBS, Toledo Clinic Nephrology, United States
• Muhammad Abdur Razzak, MD, MBBS, Dhaka Medical College, Bangladesh
• Iqbal Hamid Shah, MD, MBBS, King Saud University Medical City, Saudi Arabia
• Amit Sharma, MD, MBBS, FASN, Fortis Hospital, India
• Michiko Shimada, MD, PhD, FASN, Hirosaki University, Japan
• Jun Shoji, MD, University of California, San Francisco, United States
• Nicole S. Stankus, MD, MS, FASN, University of Chicago, United States
• Anna T. Valson, MD, Christian Medical College, India
• Suthaharan Vimalendran, MD, Orillia Soldiers Memorial Hospital, Canada
• Eranga Wijewickrama, MD, PhD, FASN, University of Colombo, Sri Lanka

Program Mission and Objectives

nephSAP® provides a learning vehicle for physicians, scientists, advanced practitioners, nurses, pharmacists, and other health professionals working and training in the field of nephrology to renew and refresh their clinical knowledge, diagnostic, and therapeutic skills. This enduring material provides learners challenging, clinically-oriented questions based on case vignettes, detailed learning objectives, a series of articles that review recent publications, and an editorial on an important and evolving topic. This combination of materials enables learners to rigorously assess their strengths and weaknesses in the broad domain of nephrology.

Target Audience

Physicians, scientists, advanced practitioners, nurses, pharmacists, and other health professionals working and training in the field of nephrology.

Accreditation Statements

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians: The American Society of Nephrology designates this internet activity (enduring material) for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to Joint Accreditation for the purpose of granting ABIM MOC credit. MOC points will be applied to only those ABIM candidates who have enrolled in the MOC program. It is your responsibility to complete the ABIM MOC enrollment process.

Original Release Date: December 2022

CME/MOC Termination Date: November 30, 2024, at 11:59 pm ET

Examination Available Online: On or before December 29, 2022

Estimated Time for Completion: 10 hours 

Self-Assessment Examination

• Answers with explanations are provided with a passing score after the first and/or second attempt
• This issue will be archived December 1, 2024, and answers with explanations will be posted on the ASN website

Method of Participation

• Read the entire issue that is supplemented by original articles in the reference lists.
• Complete the online self-assessment examination.
• Each participant is allowed two attempts to pass the examination (75% correct) for CME and MOC.
• Upon completion, review your score and incorrect answers and print your certificate.

Activity Evaluation, CE, and MOC

• Go to ASN eLEARNING CENTER (education.asn-online.org)
• Select MY ACTIVITIES from the left-hand navigation.
• Select the corresponding issue.
• Read all information on the Overview screen.
• Follow the onscreen instructions to:
  • Complete the Exam (i.e., post test),
  • Complete the Evaluation,
  • Claim credit/MOC, and
  • IMPORTANT: select the credit type that corresponds with your designation, and
  • Print a Certificate

Your ASN Transcript is available on the ASN website:

• Go to the ASN website and log in to your ASN Profile page
• Select the CME/CE Transcript tab
• View credits claimed or print a certificate with continuing education information for completed learning activities